CR20230314A - N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas - Google Patents
N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidasInfo
- Publication number
- CR20230314A CR20230314A CR20230314A CR20230314A CR20230314A CR 20230314 A CR20230314 A CR 20230314A CR 20230314 A CR20230314 A CR 20230314A CR 20230314 A CR20230314 A CR 20230314A CR 20230314 A CR20230314 A CR 20230314A
- Authority
- CR
- Costa Rica
- Prior art keywords
- salts
- compounds
- cyanothiazolidin
- carboxamides
- oxoethyl
- Prior art date
Links
- XLOXHPAFGDSZIU-UHFFFAOYSA-N N#CC(CSC1)N1C(CNC(C1=CC=NC2=CC=CC=C12)=O)=O Chemical class N#CC(CSC1)N1C(CNC(C1=CC=NC2=CC=CC=C12)=O)=O XLOXHPAFGDSZIU-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 abstract 1
- 101710178372 Prolyl endopeptidase Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos que tienen la estructura de Fórmula (I) y sales farmacéuticamente aceptables de los mismos, en donde X<sup>1</sup>, R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup> y R<sup>6</sup> son como se definen en la memoria descriptiva; composiciones farmacéuticas que comprenden dichos compuestos y sales; uso de dichos compuestos y sales para tratar o prevenir afecciones mediadas por la proteína de activación de fibroblastos prolil endopeptidasa (FAP); kits que comprenden dichos compuestos y sales; y métodos para preparar dichos compuestos y sales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063126593P | 2020-12-17 | 2020-12-17 | |
PCT/IB2021/061839 WO2022130270A1 (en) | 2020-12-17 | 2021-12-16 | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20230314A true CR20230314A (es) | 2023-08-18 |
Family
ID=79164845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20230314A CR20230314A (es) | 2020-12-17 | 2021-12-16 | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas |
Country Status (19)
Country | Link |
---|---|
US (2) | US20240101549A1 (es) |
EP (1) | EP4263535A1 (es) |
JP (1) | JP2023554405A (es) |
KR (1) | KR20230122080A (es) |
CN (1) | CN116745291A (es) |
AR (1) | AR124379A1 (es) |
AU (1) | AU2021403827A1 (es) |
CA (1) | CA3204318A1 (es) |
CL (1) | CL2023001763A1 (es) |
CO (1) | CO2023008921A2 (es) |
CR (1) | CR20230314A (es) |
DO (1) | DOP2023000124A (es) |
EC (1) | ECSP23053033A (es) |
IL (1) | IL303655A (es) |
MX (1) | MX2023007287A (es) |
PE (1) | PE20232046A1 (es) |
TW (1) | TW202239407A (es) |
UY (1) | UY39569A (es) |
WO (1) | WO2022130270A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240101549A1 (en) | 2020-12-17 | 2024-03-28 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides |
WO2023247487A1 (en) * | 2022-06-21 | 2023-12-28 | Astrazeneca Ab | Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide |
WO2023247489A1 (en) * | 2022-06-21 | 2023-12-28 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW521072B (en) | 1997-06-02 | 2003-02-21 | Meiji Seika Kaisha | 4-quinolinol derivatives and fungicides containing the same as an active ingredient used for agriculture and horticulture |
FR2795726A1 (fr) | 1999-06-30 | 2001-01-05 | Aventis Cropscience Sa | Nouveaux pyrazoles fongicides |
DE10006453A1 (de) | 2000-02-14 | 2001-08-16 | Bayer Ag | Piperidylcarbonsäuren als Integrinantagonisten |
GB0010183D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
GB0010188D0 (en) | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
ES2334858T3 (es) | 2000-08-10 | 2010-03-16 | Mitsubishi Tanabe Pharma Corporation | Derivados de prolina y uso de los mismos como farmacos. |
JP2003026698A (ja) | 2000-09-27 | 2003-01-29 | Tokyo Inst Of Technol | 新規化合物、固定化物及び蛋白質のスクリーニング方法 |
GB0125445D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
KR100998796B1 (ko) | 2003-01-31 | 2010-12-06 | 가부시키가이샤산와카가쿠켄큐쇼 | 디펩티딜 펩티다아제 iv를 저해하는 화합물 |
CA2537812C (en) * | 2003-09-26 | 2013-01-22 | Exelixis, Inc. | C-met modulators and method of use |
WO2005087742A1 (en) | 2004-03-08 | 2005-09-22 | Exelixis, Inc. | Metabolic kinase modulators and methods of use as pesticides |
TWI366438B (en) | 2004-08-12 | 2012-06-21 | Ishihara Sangyo Kaisha | Fungicidal composition containing acid amide derivative |
KR20080030652A (ko) | 2005-08-11 | 2008-04-04 | 에프. 호프만-라 로슈 아게 | Dpp-iv 억제제를 포함하는 약학 조성물 |
EP1760076A1 (en) | 2005-09-02 | 2007-03-07 | Ferring B.V. | FAP Inhibitors |
JP2010510246A (ja) | 2006-11-21 | 2010-04-02 | スミスクライン ビーチャム コーポレーション | アミド抗ウイルス化合物 |
CN102884059B (zh) | 2010-03-11 | 2015-08-26 | 大日本住友制药株式会社 | N-酰基环胺衍生物或其可药用盐 |
PL2753334T3 (pl) | 2011-08-30 | 2022-12-12 | Trustees Of Tufts College | Aktywowane przez fap inhibitory proteasomu do leczenia guzów litych |
UA110862C2 (uk) | 2011-10-07 | 2016-02-25 | Ф. Хоффманн-Ля Рош Аг | Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5 |
EP2804859B1 (en) | 2012-01-17 | 2019-06-12 | Universiteit Antwerpen | Novel fap inhibitors |
CN104582707B (zh) | 2012-07-23 | 2017-09-26 | 斯法尔制药私人有限公司 | 三嗪化合物 |
KR20160133563A (ko) | 2014-03-28 | 2016-11-22 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 다이하이드로피리미딘 화합물 및 이의 약제학적 용도 |
RU2016140870A (ru) | 2014-04-22 | 2018-05-23 | Нимбус Айрис, Инк. | Ингибиторы irak и их применения |
MX2017002985A (es) | 2014-09-10 | 2017-11-17 | Epizyme Inc | Inhibidores de smyd. |
WO2017189569A1 (en) | 2016-04-25 | 2017-11-02 | Trustees Of Tufts College | Multimediator dpp4 and fap inhibitors, and uses related thereto |
CA3036987A1 (en) | 2016-09-16 | 2018-03-22 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
CN108690043B (zh) | 2017-04-11 | 2019-10-18 | 东莞东阳光科研发有限公司 | 喹啉类衍生物及其制备方法和用途 |
US11358940B2 (en) | 2017-04-20 | 2022-06-14 | The Regents Of The University Of California | K-Ras modulators |
US11584744B2 (en) | 2017-06-23 | 2023-02-21 | University Of Washington | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them |
EP3666770A4 (en) | 2017-08-07 | 2021-04-07 | Joint Stock Company "Biocad" | NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS |
US20210177827A1 (en) | 2017-10-25 | 2021-06-17 | Children`S Medical Center Corporation | Papd5 inhibitors and methods of use thereof |
WO2019118932A1 (en) | 2017-12-15 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
CA3086172A1 (en) | 2017-12-19 | 2019-06-27 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
JP2021512949A (ja) | 2018-02-06 | 2021-05-20 | ウニベルジテート ハイデルベルク | Fap阻害物質 |
MX2021000093A (es) | 2018-07-31 | 2021-03-25 | Merck Patent Gmbh | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. |
CA3108449A1 (en) | 2018-08-08 | 2020-02-13 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active bridged piperidine derivative |
EA202190623A1 (ru) | 2018-08-27 | 2021-05-21 | Сумитомо Дайниппон Фарма Ко., Лтд. | Оптически активное азабициклическое производное |
US10815241B2 (en) | 2018-08-27 | 2020-10-27 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active azabicyclo ring derivative |
JP2022514352A (ja) * | 2018-12-21 | 2022-02-10 | プラクシス バイオテック エルエルシー | 線維芽細胞活性化タンパク質の阻害剤 |
WO2021060453A1 (ja) | 2019-09-27 | 2021-04-01 | 大日本住友製薬株式会社 | 架橋型光学活性2級アミン誘導体 |
TW202132281A (zh) | 2019-11-06 | 2021-09-01 | 南韓商柳韓洋行股份有限公司 | 吡咯啶及哌啶類化合物 |
US20240101549A1 (en) | 2020-12-17 | 2024-03-28 | Astrazeneca Ab | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)-quinoline-4-carboxamides |
-
2021
- 2021-12-16 US US18/257,123 patent/US20240101549A1/en active Pending
- 2021-12-16 TW TW110147244A patent/TW202239407A/zh unknown
- 2021-12-16 IL IL303655A patent/IL303655A/en unknown
- 2021-12-16 PE PE2023001909A patent/PE20232046A1/es unknown
- 2021-12-16 CR CR20230314A patent/CR20230314A/es unknown
- 2021-12-16 AR ARP210103519A patent/AR124379A1/es unknown
- 2021-12-16 JP JP2023536454A patent/JP2023554405A/ja active Pending
- 2021-12-16 MX MX2023007287A patent/MX2023007287A/es unknown
- 2021-12-16 CN CN202180084189.5A patent/CN116745291A/zh active Pending
- 2021-12-16 KR KR1020237023914A patent/KR20230122080A/ko unknown
- 2021-12-16 WO PCT/IB2021/061839 patent/WO2022130270A1/en active Application Filing
- 2021-12-16 UY UY0001039569A patent/UY39569A/es unknown
- 2021-12-16 CA CA3204318A patent/CA3204318A1/en active Pending
- 2021-12-16 AU AU2021403827A patent/AU2021403827A1/en active Pending
- 2021-12-16 EP EP21834914.0A patent/EP4263535A1/en active Pending
-
2023
- 2023-06-12 US US18/332,897 patent/US11858924B2/en active Active
- 2023-06-14 DO DO2023000124A patent/DOP2023000124A/es unknown
- 2023-06-15 CL CL2023001763A patent/CL2023001763A1/es unknown
- 2023-07-05 CO CONC2023/0008921A patent/CO2023008921A2/es unknown
- 2023-07-14 EC ECSENADI202353033A patent/ECSP23053033A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CO2023008921A2 (es) | 2023-07-21 |
AR124379A1 (es) | 2023-03-22 |
JP2023554405A (ja) | 2023-12-27 |
CA3204318A1 (en) | 2022-06-23 |
ECSP23053033A (es) | 2023-08-31 |
KR20230122080A (ko) | 2023-08-22 |
US20240101549A1 (en) | 2024-03-28 |
DOP2023000124A (es) | 2023-07-09 |
PE20232046A1 (es) | 2023-12-27 |
WO2022130270A1 (en) | 2022-06-23 |
US11858924B2 (en) | 2024-01-02 |
US20230312550A1 (en) | 2023-10-05 |
CN116745291A (zh) | 2023-09-12 |
UY39569A (es) | 2022-07-29 |
MX2023007287A (es) | 2023-07-03 |
TW202239407A (zh) | 2022-10-16 |
IL303655A (en) | 2023-08-01 |
CL2023001763A1 (es) | 2023-11-17 |
AU2021403827A1 (en) | 2023-07-27 |
EP4263535A1 (en) | 2023-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20230314A (es) | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)-quinolin-4-carboxamidas | |
MX2022015812A (es) | Inhibidores de cisteina proteasas y sus metodos de uso. | |
MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
EP3569601A3 (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
MX2020006128A (es) | Inhibidores de la proteina de activacion de fibroblastos. | |
CO2018009275A2 (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub) | |
BR112021023359A2 (pt) | Inibidores de g12c de kras e usos dos mesmos | |
RS54476B1 (en) | DERIVATIVES 1 - ((5-HETEROARYLTHIAZOL-2-IL) AMINOCARBONYL) PYROLIDINE-2-CARBOXAMIDE AS PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS USEFUL IN THE TREATMENT OF PROLIFERATIVE DISEASES | |
MX2009003985A (es) | Fenil-acetamidas utiles como inhibidores de cinasa de proteina. | |
WO2020132661A3 (en) | Inhibitors of fibroblast activation protein | |
PH12020550986A1 (en) | Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase | |
EA200970349A1 (ru) | Ингибиторы металлопротеазы гетероциклического происхождения | |
EA201991409A2 (ru) | Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения | |
MX2022014007A (es) | Compuestos como inhibidores de bcl-2. | |
BR112015022856A8 (pt) | inibidores de protease de cetona de epóxi de tripeptídeo e dipeptídeo | |
MX2015000746A (es) | Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k). | |
MX2021007948A (es) | Inhibidores de proteina de activacion de fibroblastos. | |
EA202192746A1 (ru) | Гетероциклические соединения и их применение | |
CL2023001367A1 (es) | Inhibidores de btk | |
ATE445644T1 (de) | Anwendung von molekülen und verfahren zur behandlung von mit mcp-1/ccr2 assoziierten krankheiten | |
TW200700057A (en) | Alpha ketoamide compounds as cysteine protease inhibitors | |
CO2022000266A2 (es) | Inhibidores de enzimas | |
ATE538796T1 (de) | Piperidin- und pyrrolidin-beta-secretase-hemmer zur behandlung von alzheimer-krankheit | |
MX2007011739A (es) | Compuestos que contienen sulfonilo como inhibidores de cisteina proteasa. | |
MX2023003183A (es) | Compuestos heterociclicos de heteroarilo y usos de los mismos. |